BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 36572677)

  • 1. A pH-responsive T
    Lu H; Chen A; Zhang X; Wei Z; Cao R; Zhu Y; Lu J; Wang Z; Tian L
    Nat Commun; 2022 Dec; 13(1):7948. PubMed ID: 36572677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatic metastases: diffusion-weighted sensitivity-encoding versus SPIO-enhanced MR imaging.
    Nasu K; Kuroki Y; Nawano S; Kuroki S; Tsukamoto T; Yamamoto S; Motoori K; Ueda T
    Radiology; 2006 Apr; 239(1):122-30. PubMed ID: 16493012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Focal liver lesions. A comparison between magnetic resonance under base conditions and after a superparamagentic contrast medium].
    Finazzo M; Midiri M; Gallo C; Bartolotta TV; Luca A
    Radiol Med; 1998 Jun; 95(6):599-607. PubMed ID: 9717542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Iron oxide/manganese oxide co-loaded hybrid nanogels as pH-responsive magnetic resonance contrast agents.
    Wang X; Niu D; Wu Q; Bao S; Su T; Liu X; Zhang S; Wang Q
    Biomaterials; 2015; 53():349-57. PubMed ID: 25890733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of Bifunctional Gadolinium-Labeled Superparamagnetic Nanoparticles (Gd-MnMEIO) for In Vivo MR Imaging of the Liver in an Animal Model.
    Kuo YT; Chen CY; Liu GC; Wang YM
    PLoS One; 2016; 11(2):e0148695. PubMed ID: 26886558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. pH-responsive theranostic nanocomposites as synergistically enhancing positive and negative magnetic resonance imaging contrast agents.
    Huang X; Yuan Y; Ruan W; Liu L; Liu M; Chen S; Zhou X
    J Nanobiotechnology; 2018 Mar; 16(1):30. PubMed ID: 29587764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Hepatic and hepatocarcinoma magnetic resonance: comparison of the results obtained with paramagnetic (gadolinium) and superparamagnetic (iron oxide particles) contrast media].
    Castoldi MC; Fauda V; Scaramuzza D; Vergnaghi D
    Radiol Med; 2000 Sep; 100(3):160-7. PubMed ID: 11148882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MR imaging with i.v. superparamagnetic iron oxide: efficacy in the detection of focal hepatic lesions.
    Winter TC; Freeny PC; Nghiem HV; Mack LA; Patten RM; Thomas CR; Elliott S
    AJR Am J Roentgenol; 1993 Dec; 161(6):1191-8. PubMed ID: 8249724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Use of SPIO-enhanced T1- and T2-weighted images for the differentiation of liver lesions: an ROC analysis].
    Stroszczynski C; Gaffke G; Gretschel S; Rambow A; Jost D; Schlecht I; Schneider U; Schicke B; Hohenberger P; Gebauer B; Felix R
    Rofo; 2003 Oct; 175(10):1368-75. PubMed ID: 14556106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection and characterization of focal liver lesions using superparamagnetic iron oxide-enhanced magnetic resonance imaging: comparison between ferumoxides-enhanced T1-weighted imaging and delayed-phase gadolinium-enhanced T1-weighted imaging.
    Takahama K; Amano Y; Hayashi H; Ishihara M; Kumazaki T
    Abdom Imaging; 2003; 28(4):525-30. PubMed ID: 14580096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatic metastases: detection with multi-detector row CT, SPIO-enhanced MR imaging, and both techniques combined.
    Onishi H; Murakami T; Kim T; Hori M; Iannaccone R; Kuwabara M; Abe H; Nakata S; Osuga K; Tomoda K; Passariello R; Nakamura H
    Radiology; 2006 Apr; 239(1):131-8. PubMed ID: 16484347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. "Magnus nano-bullets" as T
    Khatik R; Wang Z; Li F; Zhi D; Kiran S; Dwivedi P; Xu RX; Liang G; Qiu B; Yang Q
    Nanomedicine; 2019 Jan; 15(1):264-273. PubMed ID: 30442595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Manganese Oxide Nanoparticles As MRI Contrast Agents In Tumor Multimodal Imaging And Therapy.
    Cai X; Zhu Q; Zeng Y; Zeng Q; Chen X; Zhan Y
    Int J Nanomedicine; 2019; 14():8321-8344. PubMed ID: 31695370
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.